World's largest network of institutions of higher learning are found in India with more than 43,000-degree colleges, over 1100 universities and more than 1.46 Mn schools and 230 Mn students participating in modern K-12 education. India’s education which was estimated to be worth US$ 117 billion in FY20 is expected to reach US$ 225 billion by FY25. The Indian edtech market size is also expected to reach US$ 30 billion by 2031, from US$ 700-800 million in 2021. Moreover, online education sector in India is growing rapidly, with growth of US$ 2.28 billion expected during 2021-2025, at a CAGR of almost 20%.

The education sector has seen a host of reforms and improved financial outlays in recent years that could possibly transform the sector. The key growth drivers for the sector are strong technological infrastructure, improving higher education ecosystem, large English-speaking population and favourable Government policies.

Governments has provided thrust to the sector through its National Education Policy (NEP) with the focus on high-quality vocational education by setting up regional and national institutes for virology, >15,000 schools, 100 new Sainik schools, and 750 Eklavya model residential schools in tribal areas. The National Curriculum Framework for School Education (NCF) has been developed based on the National Education Policy (NEP), 2020 vision to guarantee that students have adequate time and opportunity to perform successfully. Government has also approved the “New India Literacy Programme” for the period FY22-27 to cover all the aspects of adult education to align with the National Education Policy 2020 and Budget Announcements 2022-23.

We have supported market leaders in identifying relevant opportunities while addressing assessment challenges in K-12, higher education, and the workforce. We assist clients build their brands in India through identified policy engagements with various Central and State government agencies shaping their assessment framework for education and skill development. Looked carefully at the intersection of research, training and assessment – built coalitions and executed wining propositions.

India's medical devices sector being one of the sunrise sectors is a dynamic and rapidly growing industry which has grown significantly during the last decade. India is the 4th largest Asian medical devices market and is estimated at Rs. 90,000 crore (US$ 11 billion) in 2022 and is expected to grow to US$ 50 billion by 2030 with a CAGR of 16.4 %. A comprehensive policy framework has been implemented by the Government to capitalize on the sector's primary development drivers—increasing health care spending, rising affordability, and technological advancements—in order to ensure coordinated growth. The goal of a number of programmatic interventions launched by various government departments to promote the sector's expansion is to capitalize on the inherent strengths of the Indian medical device industry, which include, among other things, a sizable pool of people with the knowledge, training, and experience needed to manufacture and research medical devices, a robust IT infrastructure for the creation of telehealth services and digital health solutions, and supportive laws and regulations from the government.

With growing demand, the country continues to offer distinct advantages for medical devices companies including a high level of technical expertise and government funding for R&D investment. The medical devices sector has been recognised as one of the ‘priority sectors’ under the government’s flagship 'Make in India' programme. USD 55 million has also been allocated as financial assistance to develop four 'Medical Device Parks' across India. The growing role of technology has once again shone the spotlight on this sector coupled with the growing role of diagnostics and NCDs such as cancer that rely heavily on medical devices.

We work with large medical device manufacturers to build national and state level engagement strategies. Map policy developments for analysing the implication on the businesses, navigate the regulatory landscape. Covering 18 states, we bring in depth expertise in crafting public private partnerships for healthcare and creating multi stakeholder collaborations with a focus on access and business expansion.

The Indian pharmaceutical industry ranks third globally in pharmaceutical production by volume and is known for its generic medicines and low-cost vaccines. Indian pharmaceutical industry plays significant role globally, supplying affordable and low cost generic drugs to millions of people across the globe.

Considered as the ‘Pharmacy of the World’, the domestic pharmaceuticals sector is valued at USD 41 billion, with a potential to reach USD 65 billion by 2024 and USD 130 billion by 2030. India is the 12th largest exporter of medical goods in the world and account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21. Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. The FDI inflows in the Indian drugs and pharmaceuticals sector reached US$ 21.46 billion between April 2000-March 2023.

The sector has been accorded high priority and under the AtmaN irbhar (self-reliant) agenda, a massive USD 2.5 billion Production Linked Incentive (PLI) scheme as well as bulk drugs park scheme has been introduced to boost the domestic production of APIs, KSMs, and bulk drugs. A National Medical Devices Policy with the vision to facilitate an orderly growth of the medical device sector to meet the public health objectives of access, affordability, quality and innovation has also been announced.

We have in depth expertise having engaged with biopharmaceutical companies, in improving access to critical drugs in the areas of communicable and non-communicable diseases through collaborative partnerships with various levels of government. We have also supported clients in identifying and executing market expansion opportunities for existing and future pipeline products, working at the intersection of policy, business, and marketing support.

The Indian pharmaceutical industry ranks third globally in pharmaceutical production by volume and is known for its generic medicines and low-cost vaccines. Indian pharmaceutical industry plays significant role globally, supplying affordable and low cost generic drugs to millions of people across the globe.

Considered as the ‘Pharmacy of the World’, the domestic pharmaceuticals sector is valued at USD 41 billion, with a potential to reach USD 65 billion by 2024 and USD 130 billion by 2030. India is the 12th largest exporter of medical goods in the world and account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21. Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. The FDI inflows in the Indian drugs and pharmaceuticals sector reached US$ 21.46 billion between April 2000-March 2023.

The sector has been accorded high priority and under the AtmaN irbhar (self-reliant) agenda, a massive USD 2.5 billion Production Linked Incentive (PLI) scheme as well as bulk drugs park scheme has been introduced to boost the domestic production of APIs, KSMs, and bulk drugs. A National Medical Devices Policy with the vision to facilitate an orderly growth of the medical device sector to meet the public health objectives of access, affordability, quality and innovation has also been announced.

We have in depth expertise having engaged with biopharmaceutical companies, in improving access to critical drugs in the areas of communicable and non-communicable diseases through collaborative partnerships with various levels of government. We have also supported clients in identifying and executing market expansion opportunities for existing and future pipeline products, working at the intersection of policy, business, and marketing support.

The Indian pharmaceutical industry ranks third globally in pharmaceutical production by volume and is known for its generic medicines and low-cost vaccines. Indian pharmaceutical industry plays significant role globally, supplying affordable and low cost generic drugs to millions of people across the globe.

Considered as the ‘Pharmacy of the World’, the domestic pharmaceuticals sector is valued at USD 41 billion, with a potential to reach USD 65 billion by 2024 and USD 130 billion by 2030. India is the 12th largest exporter of medical goods in the world and account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21. Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. The FDI inflows in the Indian drugs and pharmaceuticals sector reached US$ 21.46 billion between April 2000-March 2023.

The sector has been accorded high priority and under the AtmaN irbhar (self-reliant) agenda, a massive USD 2.5 billion Production Linked Incentive (PLI) scheme as well as bulk drugs park scheme has been introduced to boost the domestic production of APIs, KSMs, and bulk drugs. A National Medical Devices Policy with the vision to facilitate an orderly growth of the medical device sector to meet the public health objectives of access, affordability, quality and innovation has also been announced.

We have in depth expertise having engaged with biopharmaceutical companies, in improving access to critical drugs in the areas of communicable and non-communicable diseases through collaborative partnerships with various levels of government. We have also supported clients in identifying and executing market expansion opportunities for existing and future pipeline products, working at the intersection of policy, business, and marketing support.

Environment, sustainability, and impact investing are interconnected concepts that reflect a growing awareness of the need to align financial investments with environmental and social considerations. Environmental sustainability is essential for long-term economic and social well-being. Impact investing is a way to use our financial resources to promote sustainability and create positive change.

As awareness of environmental and social issues continues to grow, the integration of sustainability and impact considerations into investment strategies is likely to become even more significant. Investors, businesses, and policymakers play crucial roles in shaping the future of sustainable finance. The Indian government has taken significant strides in recent years to address environmental concerns, promote sustainable practices, and encourage impact investing. Some of the key initiatives include National Action Plan on Climate Change (NAPCC), National Clean Air Programme (NCAP), Swachh Bharat Abhiyan (Clean India Mission), National River Conservation Plan (NRCP), National Mission for Sustainable Agriculture (NMSA), National Solar Mission, Smart Cities Mission, Jal Jeevan Mission, Green Climate Fund (GCF), Social Impact Assessment (SIA), Angel Tax exemption for startups focusing on social impact, establishment of India's Impact Investing Network (IIN).

The government has also reiterated its commitment to rebuild India as a circular economy. India produces over 60 million tonnes of plastic waste annually, of which approximately 45 million tonnes are untreated. At present, India recycles only 60% of the total plastic waste produced in the country. India’s Waste Management Market is expected to reach USD 14 billion by 2025 with an annual growth rate of over 7%. Leveraging our industry experience and network to help international funds navigate the India opportunity. Identifying India partners and structuring business opportunities with a focus on the circular economy and waste management, paving the way for impact investment and environmental sustainability. Strengthened triple bottom line reporting of Indian corporates via sustainability programs.

Born to a tea planter family of Jorhat in Assam (India), Anirudh spent his formative years in the tea estates of Upper Assam. His evolution with the tea world of Assam and life as a planter’s son in the 1980s is the reason that Anirudh remains so passionate about the environment, close to the lives and culture of the tea communities, understands the changing needs of the industry, empowering its people, and uplifting its overall infrastructure.

Anirudh founded the BORBHAG Group in 2010 with the objective to enable inclusive development between business, policy and last mile implementation. With his aim to take investments to North East India and help the region prosper, Anirudh was instrumental in introducing solar and LED based solutions in the region. His ability to envision and identify investment opportunities ahead of time, strategize, plan, formulate projects and bring people together for their execution has helped him expand his outreach globally.

Today, Anirudh is sought for his significant understanding of Centre-State relations, latest policy developments, advocacy initiatives, to make investments and change happen in the remotest districts of India as well as established cities. From then, he has continued to build on this vision. Today, he is sought for his expertise in building and executing government affairs programs for large multinationals across a diverse set of sectors - identifying growth opportunities, managing business critical risks and taking new concepts from ideation to implementation – all with a focus on shared value and contributing to sustainable change. At present,BORBHAG is McLarty Associates strategic partner for India, a leading Washington-based private sector diplomacy firm, that has helped clients manage government and policy issues around the world since 1998.Anirudh is Senior Advisor, McLarty Associates and advises regularly on navigating the complex Indian policy landscape.

Anirudh was fortunate to be mentored by the sharpest Chairmen and business leaders in the auto ancillary sector at a very young age. This provided in depth exposure to the industry and national committees which has been rewarding and lasting. His thought leadership led to pioneering ideas in Public-Private-Partnerships, creation of specialized Industrial Training Institutes, the first smart village in Northeast India under the aegis of The BORBHAG Initiative Society and the redevelopment and revival of a Mughal-era park in the heart of Delhi under The Qudsia Bagh Welfare Society which he founded.

He has key experience across sectors such as healthcare, nutrition, education, power, new and renewable energy, food processing, social development and CSR initiatives. His dream to build a new-Tea-world-order however (as his wife quips) remains his first love, followed by Northeast India, his family, his plants, travel, explore and relax with some OTT programs. He currently lives in Delhi with his wife, daughter and his maverick dreams, some of which have come true and many that will.

Anirudh received his Master’s Degree in Political Studies from the Jawaharlal Nehru University (JNU), New Delhi (India), Bachelors of Arts in History, Economics & Political Science from St. Josephs’ College of Arts & Sciences, Bangalore (India) & is an alumni of The Doon School, Dehra Dun (India).